https://orcid.org/0000-0001-7123-2931
Citations (41)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Phil McEwan, Piotr Ponikowski, Tinevimbo Shiri, Giuseppe M. C. Rosano, Andrew J. S. Coats, Fabio Dorigotti, Antonio Ramirez de Arellano & Ewa A. Jankowska. (2023) Clinical and economic impact of ferric carboxymaltose treatment for iron deficiency in patients stabilized following acute heart failure: a multinational study. Journal of Medical Economics 26:1, pages 51-60.
Read now
Read now
Gaetano Bergamaschi, Flavio Caprioli, Marco Vincenzo Lenti, Luca Elli, Franco Radaelli, Emanuele Rondonotti, Caterina Mengoli, Emanuela Miceli, Chiara Ricci, Sandro Ardizzone, Maurizio Vecchi & Antonio Di Sabatino. (2022) Pathophysiology and therapeutic management of anemia in gastrointestinal disorders. Expert Review of Gastroenterology & Hepatology 16:7, pages 625-637.
Read now
Read now
Irina Blumenstein, Satish Shanbhag, Peter Langguth, Philip A Kalra, Heinz Zoller & Wendy Lim. (2021) Newer formulations of intravenous iron: a review of their chemistry and key safety aspects – hypersensitivity, hypophosphatemia, and cardiovascular safety. Expert Opinion on Drug Safety 20:7, pages 757-769.
Read now
Read now
Xenophon Kassianides, Richard Bodington & Sunil Bhandari. (2021) An evaluation of ferric derisomaltose as a treatment for anemia. Expert Review of Hematology 14:1, pages 7-29.
Read now
Read now
Xenophon Kassianides, Adil Mohammad Hazara & Sunil Bhandari. (2021) Improving the safety of intravenous iron treatments for patients with chronic kidney disease. Expert Opinion on Drug Safety 20:1, pages 23-35.
Read now
Read now
Toby Richards, Christian Breymann, Matthew J. Brookes, Stefan Lindgren, Iain C. Macdougall, Lawrence P. McMahon, Malcolm G. Munro, Elizabeta Nemeth, Giuseppe M. C. Rosano, Ingolf Schiefke & Günter Weiss. (2021) Questions and answers on iron deficiency treatment selection and the use of intravenous iron in routine clinical practice. Annals of Medicine 53:1, pages 274-285.
Read now
Read now
Juan F. Delgado, Juan Oliva, Álvaro González-Franco, Jose María Cepeda, Jose Ángel García-García, Almudena González-Domínguez, Albert Garcia-Casanovas, Silvia Jiménez Merino & Josep Comín-Colet. (2020) Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain. Journal of Medical Economics 23:12, pages 1418-1424.
Read now
Read now
Articles from other publishers (34)
Beatriz Samões, Bruna Silva, Ana Martins, Daniela Oliveira, Frederico Rajão Martins, Diogo Fonseca, Lúcia Costa & Miguel Bernardes. (2023) Hypophosphatemic osteomalacia induced by intravenous iron therapy: a case report. Joint Bone Spine 90:5, pages 105586.
Crossref
Crossref
Heinz Zoller, Myles Wolf, Irina Blumenstein, Christian Primas, Stefan Lindgren, Lars L Thomsen, Walter Reinisch & Tariq Iqbal. (2023) Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial. Gut 72:4, pages 644-653.
Crossref
Crossref
Giuseppe MC Rosano, Kamyar Kalantar‐Zadeh & Ewa A. Jankowska. (2023) Hypophosphataemia risk associated with ferric carboxymaltose in heart failure: A pooled analysis of clinical trials. ESC Heart Failure 10:2, pages 1294-1304.
Crossref
Crossref
Michel Grino, Marine Rigaux, Anne-Violette Lagarde, Vincent Robert, Charlotte Papailhau & Marie-Bénédicte Vincentelli. (2023) Hypophosphorémie après traitement par fer injectable chez l’adulte : comparaison entre le carboxymaltose ferrique et l’hydroxyde ferrique-saccharose. Annales Pharmaceutiques Françaises.
Crossref
Crossref
Ashley E. Benson, Joseph J. Shatzel, Kim S. Ryan, Madeline A. Hedges, Kylee Martens, Joseph E. Aslan & Jamie O. Lo. (2022) The incidence, complications, and treatment of iron deficiency in pregnancy. European Journal of Haematology 109:6, pages 633-642.
Crossref
Crossref
Mihai Lupu, Diana Tudor & Adriana Filip. (2022) Iron metabolism and cardiovascular disease: Basic to translational purviews and therapeutical approach. Revista Portuguesa de Cardiologia 41:12, pages 1037-1046.
Crossref
Crossref
Keerthana Haridas & Alice Yau. (2022) Severe Hypophosphatemia Occurring After Repeated Exposure to a Parenteral Iron Formulation. Case Reports in Endocrinology 2022, pages 1-3.
Crossref
Crossref
Johannes M. M. Boots & Rogier A. M. Quax. (2022) High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment. Drug Safety 45:10, pages 1019-1036.
Crossref
Crossref
Annabel Biruete, Corinne E Metzger, Neal X Chen, Elizabeth A Swallow, Curtis Vrabec, Erica L Clinkenbeard, Alexander J Stacy, Shruthi Srinivasan, Kalisha O'Neill, Keith G Avin, Matthew R Allen & Sharon M Moe. (2022) Effects of ferric citrate and intravenous iron sucrose on markers of mineral, bone, and iron homeostasis in a rat model of CKD-MBD. Nephrology Dialysis Transplantation 37:10, pages 1857-1867.
Crossref
Crossref
Aysegül Aksan, Fred Zepp, Sangeetha Anand & Jürgen Stein. (2022) Intravenous ferric carboxymaltose for the management of iron deficiency and iron deficiency anaemia in children and adolescents: a review. European Journal of Pediatrics 181:11, pages 3781-3793.
Crossref
Crossref
Antonio Ramirez de Arellano, Nicholas Norton, Dana Enkusson, Linnea Oldsberg, Yvonne Thomson, Mathias Lilja & Aysegül Aksan. (2022) Cost-Effectiveness of Intravenous Iron Formulations in Patients with Iron Deficiency Anaemia and Inflammatory Bowel Disease, in a Swedish Regional Setting Using Real-World Tender Prices. GastroHep 2022, pages 1-10.
Crossref
Crossref
Mousa Ghelichi-Ghojogh, Mohammad fararouei, Mozhgan Seif, Bahram Shahryari & Maryam Pakfetrat. (2021) Impact of social and clinical factors on the diagnostic delay of chronic kidney disease: an evaluation study. International Urology and Nephrology 54:7, pages 1603-1612.
Crossref
Crossref
Jonathan W. Bazeley & Jay B. Wish. (2022) Recent and Emerging Therapies for Iron Deficiency in Anemia of CKD: A Review. American Journal of Kidney Diseases 79:6, pages 868-876.
Crossref
Crossref
Tatiane Vilaca, Nalini Velmurugan, Christopher Smith, Bo Abrahamsen & Richard Eastell. (2022) Osteomalacia as a Complication of Intravenous Iron Infusion: A Systematic Review of Case Reports. Journal of Bone and Mineral Research 37:6, pages 1188-1199.
Crossref
Crossref
Michael Auerbach, Maureen M. Achebe, Lars L. Thomsen & Richard J. Derman. (2022) Efficacy and safety of ferric derisomaltose (FDI) compared with iron sucrose (IS) in patients with iron deficiency anemia after bariatric surgery. Obesity Surgery 32:3, pages 810-818.
Crossref
Crossref
Benedikt Schaefer, Moritz Tobiasch, Sonja Wagner, Bernhard Glodny, Herbert Tilg, Myles Wolf & Heinz Zoller. (2022) Hypophosphatemia after intravenous iron therapy: Comprehensive review of clinical findings and recommendations for management. Bone 154, pages 116202.
Crossref
Crossref
Fahad Aljuraibah, Justine Bacchetta, Maria Luisa Brandi, Pablo Florenzano, Muhammad K Javaid, Outimaija Mäkitie, Adalbert Raimann, Mariano Rodriguez, Heide Siggelkow, Dov Tiosano, Marc Vervloet & Carsten A Wagner. (2021) An Expert Perspective on Phosphate Dysregulation With a Focus on Chronic Hypophosphatemia. Journal of Bone and Mineral Research 37:1, pages 12-20.
Crossref
Crossref
Ahmed Abu-Zaid, Duha Magzoub, Mohammad Abdulrahman Aldehami, Abdulrahman Adel Behiry, Akshaya Srikanth Bhagavathula & Raouf Hajji. (2021) The Effect of Iron Supplementation on FGF23 in Chronic Kidney Disease Patients: a Systematic Review and Time-Response Meta-Analysis. Biological Trace Element Research 199:12, pages 4516-4524.
Crossref
Crossref
Shreedhar Adhikari, Omar Mamlouk, Helbert Rondon-Berrios & Biruh T Workeneh. (2021) Hypophosphatemia in cancer patients. Clinical Kidney Journal 14:11, pages 2304-2315.
Crossref
Crossref
Maria Luisa Brandi, Gavin P.R. Clunie, Pascal Houillier, Suzanne M. Jan de Beur, Salvatore Minisola, Ralf Oheim & Lothar Seefried. (2021) Challenges in the management of tumor-induced osteomalacia (TIO). Bone 152, pages 116064.
Crossref
Crossref
Hans-Klaus Goischke. (2021) Neue Aspekte zur Eisentherapie des RLS in der Praxis – Teil 2New Aspects Regarding Iron Treatment for RLS in Daily Practice—Part 2. psychopraxis. neuropraxis 24:5, pages 304-309.
Crossref
Crossref
Kathleen H McGrath & Patricia W R Khoo. (2021) Hypophosphataemia Following Ferric Carboxymaltose Infusion. Journal of Paediatrics and Child Health 57:9, pages 1546-1546.
Crossref
Crossref
Mitchell H. Rosner & Amanda DeMauro Renaghan. (2021) Disorders of Divalent Ions (Magnesium, Calcium, and Phosphorous) in Patients With Cancer. Advances in Chronic Kidney Disease 28:5, pages 447-459.e1.
Crossref
Crossref
John A. Glaspy, Myles Wolf & William E. Strauss. (2021) Intravenous Iron-Induced Hypophosphatemia: An Emerging Syndrome. Advances in Therapy 38:7, pages 3531-3549.
Crossref
Crossref
Deborah Rund. (2020) Intravenous iron: do we adequately understand the short‐ and long‐term risks in clinical practice?. British Journal of Haematology 193:3, pages 466-480.
Crossref
Crossref
Emel ISIKTAS SAYILAR. (2021) Kronik böbrek hastalarında ferrik karboksimaltoz tedavisinin serum fosfor düzeyine etkisi. Cukurova Medical Journal 46:1, pages 266-272.
Crossref
Crossref
Paul Wong, Michael White, Federico Tozzi, Susanne G. Warner, Yanhgee Woo, Gagandeep Singh, Yuman Fong & Laleh Melstrom. (2020) Implications of Postpancreatectomy Hypophosphatemia. The American Surgeon 87:1, pages 61-67.
Crossref
Crossref
Lindsay Dowhan Hoag & T. S. Dharmarajan. 2020. Geriatric Gastroenterology. Geriatric Gastroenterology
1
29
.
Lindsay Dowhan Hoag & T. S. Dharmarajan. 2021. Geriatric Gastroenterology. Geriatric Gastroenterology
735
763
.
Eduardo Luis Callejas-Moraga, Enrique Casado, Marta Gomez-Nuñez & Ana Paula Caresia-Aroztegui. (2020) Severe osteomalacia with multiple insufficiency fractures secondary to intravenous iron therapy in a patient with Rendu-Osler-Weber syndrome. Bone Reports 13, pages 100712.
Crossref
Crossref
Giuseppe Rosano, Ingolf Schiefke, Udo-Michael Göhring, Vincent Fabien, Stefano Bonassi & Jürgen Stein. (2020) A Pooled Analysis of Serum Phosphate Measurements and Potential Hypophosphataemia Events in 45 Interventional Trials with Ferric Carboxymaltose. Journal of Clinical Medicine 9:11, pages 3587.
Crossref
Crossref
Hulya Ozsahin, Michela Schaeppi, Michael Bernimoulin, Magali Allard, Clémence Guidard & Frank van den Ouweland. (2020) Intravenous ferric carboxymaltose for iron deficiency anemia or iron deficiency without anemia after poor response to oral iron treatment: Benefits and risks in a cohort of 144 children and adolescents. Pediatric Blood & Cancer 67:10.
Crossref
Crossref
Ioannis Bellos, Maximos Frountzas & Vasilios Pergialiotis. (2020) Comparative Risk of Hypophosphatemia Following the Administration of Intravenous Iron Formulations: A Network Meta-Analysis. Transfusion Medicine Reviews 34:3, pages 188-194.
Crossref
Crossref
Xenophon Kassianides & Prof Sunil Bhandari. (2022) Methodology and Baseline Data of a Comparative Exploratory Double-Blinded Randomized Study of Intravenous Iron on Fibroblast Growth Factor 23 and Phosphate in Chronic Kidney Disease. SSRN Electronic Journal.
Crossref
Crossref